Maraviroc in Patients Undergoing Non-Myeloablative Allogeneic Stem-Cell Transplantation
| Status: | Archived |
|---|---|
| Conditions: | Blood Cancer, Orthopedic, Hematology |
| Therapuetic Areas: | Hematology, Oncology, Orthopedics / Podiatry |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | June 2009 |
| End Date: | December 2013 |
Safety and Efficacy of Maraviroc, a CCR5-inhibitor in Prophylaxis of Graft-Versus-Host Disease in Patients Undergoing Non-Myeloablative Allogeneic Stem-Cell Transplantation
This study investigates the effectiveness and safety of Maraviroc (an oral medication given
twice daily given in addition to the standard GVHD prophylaxis) in preventing Graft versus
Host Disease (GVHD) in patients undergoing non-myeloablative allogeneic stem-cell
transplantation (SCT). Subjects will receive Maraviroc bid (in addition to standard GVHD
prophylaxis) beginning after the last dose of the chemotherapy conditioning regimen until
day 30 after stem-cell infusion.
We found this trial at
1
site
Click here to add this to my saved trials
